RNAi Screening of the Kinome to Identify Mediators of proliferation and trastuzumab (Herceptin) resistance in HER2 Breast Cancers

Breast cancers with overexpression or amplification of the HER2 tyrosine kinase receptor are more aggressive, resistant to chemotherapy, and associated with a worse prognosis. Currently, these breast cancers are treated with the monoclonal antibody trastuzumab (Herceptin®). Unfortunately, not all pa...

Full description

Bibliographic Details
Main Author: Lapin, Valentina
Other Authors: Mak, Tak Wah
Language:en_ca
Published: 2012
Subjects:
Online Access:http://hdl.handle.net/1807/35712